Brain Advance Access originally published online on January 9, 2006
Brain 2006 129(3):584-594; doi:10.1093/brain/awh721
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease
1 Department of Clinical Neurological Sciences, University of Western Ontario London, Ontario, Canada, 2 Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA and 3 Department of Clinical Neurology, University of Oxford, Oxford, UK
Correspondence and reprint requests to: Professor G. C. Ebers, Department of Clinical Neurology, University of Oxford, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK E-mail: george.ebers{at}clneuro.ox.ac.uk
The clinical features of relapses and progression largely define multiple sclerosis phenotypes. A relapsing course is followed by chronic progression in some 80% of cases within 2 decades. The relationship between these phases and long-term outcome remains uncertain. We have analysed these clinical features within a well-studied natural history cohort with mean follow-up of 25 years. For the entire cohort, median times to reach Disability Status Scale (DSS) 6, 8 and 10 were 12.7, 20.6 and 43.9 years, respectively. Among 824 attack-onset patients, the great majority entered a progressive phase with a mean time to progression of 10.4 years. The effects of relapses often cloud the clinical onset of progression. However, there are circumstances where onset of progression is early, relatively discrete and identifiable at DSS of 2 or less. Three subgroups allow for clarity of outcome comparison and they are (i) cases of primary progressive (PP) disease, (ii) attack-onset disease where only a single attack has occurred before onset of progression (SAP) and (iii) secondary progressive (SP) disease where recovery from relapses allows recognition of the earliest clinical stages when progression begins. Here we compare survival curves in these three groups. Among cohorts of SAP (n = 140), PP (n = 219) and SP (n = 146) where progression was stratified by DSS at its onset, there was no difference in time to DSS 6, 8 and 10. These findings demonstrate that the progressive course is independent of relapses either preceding the onset of relapse-free progression or subsequent to it. Among SAP patients, the degree of recovery from the single defining exacerbation had no significant effect on outcome. The site of the original attack was not usually where progression began. The relatively stereotyped nature of the progressive phase seen in all progressive phenotypes suggests regional and/or functional differential susceptibility to a process that appears degenerative in nature. The highly prevalent distal corticospinal tract dysfunction in progressive disease and the pathologically demonstrated selective axonal loss seen in this tract raises the possibility of a dying back central axonopathy, at least in part independent of plaque location or burden. Despite considerable individual variation, the progressive course of disability seen in groups of PP, SAP and SP-DSS2 is similarly stereotyped in quality and pace and may entail mechanisms common to all forms of progressive multiple sclerosis. The possibility that this is the primary process in some cases must be considered.
Key Words: multiple sclerosis; natural history; progressive clinical course
Abbreviations: DSS = Disability Status Scale; PP = primary progressive; RR = relapsing–remitting; SP = secondary progressive; SAP = single-attack progressive
Received October 19, 2005. Revised November 15, 2005. Accepted November 15, 2005.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A Wilkins and N Scolding Protecting axons in multiple sclerosis Multiple Sclerosis, September 1, 2008; 14(8): 1013 - 1025. [Abstract] [PDF]
|
|
|
|
|
|
M Koch, M Uyttenboogaart, A van Harten, M Heerings, and J De Keyser Fatigue, depression and progression in multiple sclerosis Multiple Sclerosis, July 1, 2008; 14(6): 815 - 822. [Abstract] [PDF]
|
|
|
|
|
|
M Koch, M Uyttenboogaart, A van Harten, and J De Keyser Factors associated with the risk of secondary progression in multiple sclerosis Multiple Sclerosis, July 1, 2008; 14(6): 799 - 803. [Abstract] [PDF]
|
|
|
|
|
|
M Koch, J De Keyser, and H Tremlett Timing of birth and disease progression in multiple sclerosis Multiple Sclerosis, July 1, 2008; 14(6): 793 - 798. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Sawcer The complex genetics of multiple sclerosis: pitfalls and prospects Brain, May 18, 2008; (2008) awn081v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Leone, S. Bonissoni, L. Collimedaglia, F. Tesser, S. Calzoni, A. Stecco, P. Naldi, and F. Monaco Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study Multiple Sclerosis, May 1, 2008; 14(4): 485 - 493. [Abstract] [PDF]
|
|
|
|
|
|
H. Tremlett, Yinshan Zhao, and V. Devonshire Natural history of secondary-progressive multiple sclerosis Multiple Sclerosis, April 1, 2008; 14(3): 314 - 324. [Abstract] [PDF]
|
|
|
|
|
|
M. Koch, M. Uyttenboogaart, M. Heerings, D. Heersema, J. Mostert, and J. De Keyser Progression in familial and nonfamilial MS Multiple Sclerosis, April 1, 2008; 14(3): 300 - 306. [Abstract] [PDF]
|
|
|
|
|
|
L. K. Fisniku, P. A. Brex, D. R. Altmann, K. A. Miszkiel, C. E. Benton, R. Lanyon, A. J. Thompson, and D. H. Miller Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis Brain, March 1, 2008; 131(3): 808 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Koch, A. van Harten, M. Uyttenboogaart, and J. De Keyser Cigarette smoking and progression in multiple sclerosis Neurology, October 9, 2007; 69(15): 1515 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Wingerchuk, S. J. Pittock, C. F. Lucchinetti, V. A. Lennon, and B. G. Weinshenker A secondary progressive clinical course is uncommon in neuromyelitis optica Neurology, February 20, 2007; 68(8): 603 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Natural History of Multiple Sclerosis Journal Watch Neurology, June 22, 2006; 2006(622): 4 - 4. [Full Text]
|
|
|
|
|
|
G. C. DeLuca, K. Williams, N. Evangelou, G. C. Ebers, and M. M. Esiri The contribution of demyelination to axonal loss in multiple sclerosis Brain, June 1, 2006; 129(6): 1507 - 1516. [Abstract] [Full Text] [PDF]
|
|